Charles River Laboratories Announces Closing of Senior Notes Offering
October 23 2019 - 4:30PM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL)
announced today that it has closed its previously announced
offering of $500 million in aggregate principal amount of its 4.25%
senior notes due 2028 (the “notes”) in an unregistered
offering.
The notes have not been, and will not be, registered under the
Securities Act of 1933, as amended (the “Securities Act”), or under
the securities laws of any other jurisdiction. Unless they are
registered, the notes may be offered only in transactions that are
exempt from registration under the Securities Act and applicable
state securities laws. The notes were offered only to persons
reasonably believed to be qualified institutional buyers under Rule
144A under the Securities Act and to non-U.S. persons outside the
United States under Regulation S of the Securities Act.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the notes, nor shall there be any
sale of the notes in any state or jurisdiction in which such an
offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
Caution Concerning Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “would,”
“will,” “may,” “estimate,” “plan,” “outlook,” and “project” and
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters.
Forward-looking statements are based on Charles River’s current
expectations and beliefs, and involve a number of risks and
uncertainties that are difficult to predict and that could cause
actual results to differ materially from those stated or implied by
the forward-looking statements. A further description of these
risks, uncertainties, and other matters can be found in the Risk
Factors detailed in Charles River's Annual Report on Form 10-K as
filed on February 13, 2019 and in its Quarterly Report on Form 10-Q
as filed on July 31, 2019, as well as other filings we make with
the Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and
events may differ materially from results and events currently
expected by Charles River, and Charles River assumes no obligation
and expressly disclaims any duty to update information contained in
this news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191023005772/en/
Investor Contact: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com Media Contact:
Amy Cianciaruso Corporate Vice President, Public Relations
781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Sep 2023 to Sep 2024